Cara Therapeutics, Inc. (CARA) to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarijuanaStocks • 04/02/24
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/02/24
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024GlobeNewsWire • 03/07/24
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/04/24
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024GlobeNewsWire • 02/12/24
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026GlobeNewsWire • 01/22/24
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic DermatitisGlobeNewsWire • 12/18/23
Earnings Preview: Cara Therapeutics (CARA) Q3 Earnings Expected to DeclineZacks Investment Research • 11/06/23
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare RoyaltyGlobeNewsWire • 11/02/23
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023GlobeNewsWire • 10/23/23
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis PatientsGlobeNewsWire • 09/25/23
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceGlobeNewsWire • 08/02/23
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023GlobeNewsWire • 07/24/23